ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Editing

First in vivo CRISPR gene editing in humans

by Ryan Cross
March 7, 2020 | APPEARED IN VOLUME 98, ISSUE 9

 

Editas Medicine and Allergan have begun a clinical trial of a CRISPR gene-editing therapy designed to remove a genetic mutation that causes a rare form of inherited blindness. The therapy, which is packaged in a virus, is injected under the retina of the eye during surgery. While other groups have used CRISPR on blood and immune cells removed from the body, the trial by Editas and Allergan marks the first time CRISPR has been used directly inside the body, a feat called in vivo gene editing.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment